Home » Stocks » TARA

ArTara Therapeutics, Inc. (TARA)

Stock Price: $8.79 USD -0.24 (-2.66%)
Updated May 12, 2021 4:00 PM EDT - Market closed
After-hours: $8.84 +0.05 (0.57%) May 12, 6:11 PM
Market Cap 100.83M
Revenue (ttm) n/a
Net Income (ttm) -37.38M
Shares Out 11.23M
EPS (ttm) -4.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $8.79
Previous Close $9.03
Change ($) -0.24
Change (%) -2.66%
Day's Open 8.98
Day's Range 8.75 - 9.04
Day's Volume 114,256
52-Week Range 8.72 - 67.08

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End -

6 days ago - GlobeNewsWire

Novavax, Inc. (NASDAQ: NVAX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Protara Therapeutics, Inc. (NASDAQ: TARA) are among the biotech movers Friday. Novavax Moves On Mid-stage Malaria Vaccine Dat...

Other stocks mentioned: INO, NVAX
2 weeks ago - Benzinga

Company to conduct additional clinical study to support submission of a Biologics License Application for TARA-002 in Lymphatic Malformations Company to conduct additional clinical study to support subm...

2 weeks ago - GlobeNewsWire

NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with si...

3 weeks ago - GlobeNewsWire

NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with si...

3 weeks ago - GlobeNewsWire

- Initiation of Phase 1 Trial of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer on Track to Commence by Year-End -

2 months ago - GlobeNewsWire

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...

3 months ago - GlobeNewsWire

There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they believe they can profit remarkably from their investments after the market has reassesse...

Other stocks mentioned: AKUS, PMVP
3 months ago - GuruFocus

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...

5 months ago - GlobeNewsWire

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...

5 months ago - GlobeNewsWire

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...

5 months ago - GlobeNewsWire

- On T rack to Complete GMP Batch Runs in Mid-2021 to C onfirm C omparability B etween TARA-002 and OK-432 - - Expect to I nitiate Phase 1 T rial for TARA-002 in P atients with N on- M uscle I nvasive B...

6 months ago - GlobeNewsWire

NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...

6 months ago - GlobeNewsWire

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...

6 months ago - GlobeNewsWire

NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with ...

7 months ago - GlobeNewsWire

NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with ...

7 months ago - GlobeNewsWire

- Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs -

8 months ago - GlobeNewsWire

About TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed ... [Read more...]

Industry
Biotechnology
CEO
Jesse Shefferman
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
TARA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price forecast is 41.50, which is an increase of 372.13% from the latest price.

Price Target
$41.50
(372.13% upside)
Analyst Consensus: Strong Buy